March 8, 2018 09:07 AM ESTUpdated 09:21 AM

Nimbus founding CSO Rosana Kapeller leaves to explore exec role; AI startup BioXcel pockets $60M from IPO

Amber Tong

→ Having helped turn “the vision of computational-based drug discovery into reality” at Nimbus Therapeutics, founding CSO Rosana Kapeller has decided it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nimbus founding CSO Rosana Kapeller leaves to explore exec role; AI startup BioXcel pockets $60M from IPO

Amber Tong

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?

Nim­bus found­ing CSO Rosana Kapeller leaves to ex­plore ex­ec role; AI start­up BioX­cel pock­ets $60M from IPO

Amber Tong

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Nimbus founding CSO Rosana Kapeller leaves to explore exec role; AI startup BioXcel pockets $60M from IPO

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?